Bicycle Therapeutics plc Earnings Per Share, Basic and Diluted
Bicycle Therapeutics plc (BCYC) reported Earnings Per Share, Basic and Diluted of -$0.73 per share for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-06.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2021-05-06
- Bicycle Therapeutics plc earnings per share, basic and diluted for the quarter ending 2021-03-31 was -$0.73.
- Bicycle Therapeutics plc earnings per share, basic and diluted for the quarter ending 2020-12-31 was -$0.83.
- Bicycle Therapeutics plc earnings per share, basic and diluted for the quarter ending 2020-09-30 was -$0.52.
- Bicycle Therapeutics plc earnings per share, basic and diluted for the quarter ending 2020-06-30 was -$0.67.
- Bicycle Therapeutics plc earnings per share, basic and diluted for fiscal 2020 was -$2.66.
- Bicycle Therapeutics plc earnings per share, basic and diluted for fiscal 2019 was -$2.77.
- Bicycle Therapeutics plc earnings per share, basic and diluted for fiscal 2018 was -$49.78.
- Bicycle Therapeutics plc earnings per share, basic and diluted for fiscal 2017 was -$48.81.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2021-03-31 | -$0.73 10-Q · filed 2021-05-06 | -$1.56 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$2.10 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$2.77 derived: net income ÷ weighted average shares · filed 2023-02-28 |
| 2020-12-31 | -$0.83 10-K · filed 2021-03-11 | -$1.36 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$2.03 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$2.66 10-K · filed 2021-03-11 |
| 2020-09-30 | -$0.52 10-K · filed 2021-03-11 | -$1.19 derived: net income ÷ weighted average shares · filed 2021-11-04 | -$1.81 10-Q · filed 2020-11-05 | -$2.07 derived: net income ÷ weighted average shares · filed 2022-03-01 |
| 2020-06-30 | -$0.67 10-K · filed 2021-03-11 | -$1.30 10-Q · filed 2020-08-05 | -$1.55 derived: net income ÷ weighted average shares · filed 2022-03-01 | -$2.08 derived: net income ÷ weighted average shares · filed 2022-03-01 |
| 2020-03-31 | -$0.63 10-Q · filed 2021-05-06 | -$0.88 derived: net income ÷ weighted average shares · filed 2022-03-01 | -$1.41 derived: net income ÷ weighted average shares · filed 2022-03-01 | -$2.32 derived: net income ÷ weighted average shares · filed 2022-03-01 |
| 2019-12-31 | -$0.25 10-K · filed 2021-03-11 | -$0.78 derived: net income ÷ weighted average shares · filed 2022-03-01 | -$1.68 derived: net income ÷ weighted average shares · filed 2022-03-01 | -$2.77 10-K · filed 2021-03-11 |
| 2019-09-30 | -$0.53 10-K · filed 2021-03-11 | -$1.56 derived: net income ÷ weighted average shares · filed 2021-03-11 | -$3.00 10-Q · filed 2020-11-05 | -$4.95 derived: net income ÷ weighted average shares · filed 2021-03-11 |
| 2019-06-30 | -$1.40 10-K · filed 2021-03-11 | -$4.08 10-Q · filed 2020-08-05 | -$8.12 derived: net income ÷ weighted average shares · filed 2021-03-11 | -$13.70 derived: net income ÷ weighted average shares · filed 2021-03-11 |
| 2019-03-31 | -$7.80 10-K · filed 2021-03-11 | -$19.66 derived: net income ÷ weighted average shares · filed 2021-03-11 | -$35.29 derived: net income ÷ weighted average shares · filed 2021-03-11 | -$47.12 derived: net income ÷ weighted average shares · filed 2021-03-11 |
| 2018-12-31 | -$13.19 10-K · filed 2020-03-10 | -$30.59 derived: net income ÷ weighted average shares · filed 2021-03-11 | -$42.69 derived: net income ÷ weighted average shares · filed 2021-03-11 | -$49.78 10-K · filed 2021-03-11 |
| 2018-09-30 | -$17.73 10-K · filed 2020-03-10 | -$29.68 derived: net income ÷ weighted average shares · filed 2020-03-10 | -$36.44 10-Q · filed 2019-11-07 | |
| 2018-06-30 | -$11.85 10-K · filed 2020-03-10 | -$18.38 10-Q · filed 2019-08-08 | ||
| 2018-03-31 | -$6.38 10-K · filed 2020-03-10 | |||
| 2017-12-31 | -$48.81 10-K · filed 2020-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |